231 related articles for article (PubMed ID: 21532888)
1. p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer.
Meng F; Zhang H; Liu G; Kreike B; Chen W; Sethi S; Miller FR; Wu G
Neoplasia; 2011 May; 13(5):472-82. PubMed ID: 21532888
[TBL] [Abstract][Full Text] [Related]
2. Calycosin suppresses breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways.
Chen J; Hou R; Zhang X; Ye Y; Wang Y; Tian J
PLoS One; 2014; 9(3):e91245. PubMed ID: 24618835
[TBL] [Abstract][Full Text] [Related]
3. ErbB2 and p38γ MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis.
Xu M; Ren Z; Wang X; Comer A; Frank JA; Ke ZJ; Huang Y; Zhang Z; Shi X; Wang S; Luo J
Mol Cancer; 2016 Jul; 15(1):52. PubMed ID: 27416801
[TBL] [Abstract][Full Text] [Related]
4. Impact of p38γ mitogen-activated protein kinase (MAPK) on MDA-MB-231 breast cancer cells using metabolomic approach.
Chen H; Wang X; Guo F; Li P; Peng D; He J
Int J Biochem Cell Biol; 2019 Feb; 107():6-13. PubMed ID: 30447427
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Salmonella-induced IL-6 production in Caco-2 cells by PJ-34, PARP-1 inhibitor: involvement of PI3K, p38 MAPK, ERK, JNK, and NF-kappaB.
Huang FC
Mediators Inflamm; 2009; 2009():103890. PubMed ID: 20204057
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation and stabilization of topoisomerase IIα protein by p38γ mitogen-activated protein kinase sensitize breast cancer cells to its poisons.
Qi X; Hou S; Lepp A; Li R; Basir Z; Lou Z; Chen G
J Biol Chem; 2011 Oct; 286(41):35883-35890. PubMed ID: 21878638
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation.
Radnai B; Antus C; Racz B; Engelmann P; Priber JK; Tucsek Z; Veres B; Turi Z; Lorand T; Sumegi B; Gallyas F
Mol Cancer; 2012 May; 11():34. PubMed ID: 22583868
[TBL] [Abstract][Full Text] [Related]
8. PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.
Szanto A; Hellebrand EE; Bognar Z; Tucsek Z; Szabo A; Gallyas F; Sumegi B; Varbiro G
Biochem Pharmacol; 2009 Apr; 77(8):1348-57. PubMed ID: 19426673
[TBL] [Abstract][Full Text] [Related]
9. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.
Juvekar A; Burga LN; Hu H; Lunsford EP; Ibrahim YH; Balmañà J; Rajendran A; Papa A; Spencer K; Lyssiotis CA; Nardella C; Pandolfi PP; Baselga J; Scully R; Asara JM; Cantley LC; Wulf GM
Cancer Discov; 2012 Nov; 2(11):1048-63. PubMed ID: 22915751
[TBL] [Abstract][Full Text] [Related]
10. Role of p38γ MAPK in regulation of EMT and cancer stem cells.
Xu M; Wang S; Wang Y; Wu H; Frank JA; Zhang Z; Luo J
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3605-3617. PubMed ID: 30251680
[TBL] [Abstract][Full Text] [Related]
11. p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion.
Qi X; Tang J; Loesch M; Pohl N; Alkan S; Chen G
Cancer Res; 2006 Aug; 66(15):7540-7. PubMed ID: 16885352
[TBL] [Abstract][Full Text] [Related]
12. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
[TBL] [Abstract][Full Text] [Related]
13. Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 activation.
Racz B; Hanto K; Tapodi A; Solti I; Kalman N; Jakus P; Kovacs K; Debreceni B; Gallyas F; Sumegi B
Free Radic Biol Med; 2010 Dec; 49(12):1978-88. PubMed ID: 20920579
[TBL] [Abstract][Full Text] [Related]
14. RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway.
Li Q; Li M; Wang YL; Fauzee NJ; Yang Y; Pan J; Yang L; Lazar A
Cell Physiol Biochem; 2012; 29(3-4):361-72. PubMed ID: 22508044
[TBL] [Abstract][Full Text] [Related]
15. PJ-34 inhibits PARP-1 expression and ERK phosphorylation in glioma-conditioned brain microvascular endothelial cells.
Motta C; D'Angeli F; Scalia M; Satriano C; Barbagallo D; Naletova I; Anfuso CD; Lupo G; Spina-Purrello V
Eur J Pharmacol; 2015 Aug; 761():55-64. PubMed ID: 25934569
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
17. p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior.
Rosenthal DT; Iyer H; Escudero S; Bao L; Wu Z; Ventura AC; Kleer CG; Arruda EM; Garikipati K; Merajver SD
Cancer Res; 2011 Oct; 71(20):6338-49. PubMed ID: 21862636
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.
Mariano G; Ricciardi MR; Trisciuoglio D; Zampieri M; Ciccarone F; Guastafierro T; Calabrese R; Valentini E; Tafuri A; Del Bufalo D; Caiafa P; Reale A
Oncotarget; 2015 Jun; 6(17):15008-21. PubMed ID: 25938539
[TBL] [Abstract][Full Text] [Related]
19. p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis.
Wang F; Qi XM; Wertz R; Mortensen M; Hagen C; Evans J; Sheinin Y; James M; Liu P; Tsai S; Thomas J; Mackinnon A; Dwinell M; Myers CR; Bartrons Bach R; Fu L; Chen G
Cancer Res; 2020 Aug; 80(16):3251-3264. PubMed ID: 32580961
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer.
Liu JJ; Ho JY; Lee HW; Baik MW; Kim O; Choi YJ; Hur SY
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
